Articles From: BIOLASE® to Host Third Quarter Financial Results Conference Call on November 4, 2014 to BioMed Realty Announces Repurchase At Option Of Holders And Redemption Of 3.75% Exchangeable Senior Notes Due 2030


BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, announced today that the Company will host a conference call on Tuesday, November 4th, at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter and nine months ended September 30, 2014, and to answer questions.
Sign-up for BIOLASE® to Host Third Quarter Financial Results Conference Call on November 4, 2014 investment picks
Year-to-date Core Product Revenue up 27% Over 2013 BOTHELL, Wash.
Sign-up for BioLife Solutions Announces Preliminary Revenue for Q3 2014 of $1.2 Million investment picks
President-Elect of the Society for Cryobiology and Former Cell Therapy Executive Join Leading Clinicians, Developers, and Consultants in the Biobanking, Drug Discovery, and Regenerative Medicine Markets BOTHELL, Wash.
Sign-up for BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board investment picks
Conference Call and Webcast at 4:30pm Eastern Time BOTHELL, Wash.
Sign-up for BioLife Solutions Announces Third Quarter 2014 Results investment picks
HypoThermosol® and CryoStor® Embedded in Internal Cell Therapy Candidates and Numerous Mutual Customer Regenerative Medicine Applications BOTHELL, Wash.
Sign-up for BioLife Solutions Biopreservation Media Products Used at NeoStem Subsidiary Progenitor Cell Therapy investment picks
Super-insulating Shippers Transmit Payload Location and Critical Status Information to Enable Cloud-based Cold Chain Management BOTHELL, Wash.
Sign-up for BioLife Solutions Forms biologistex CCM(SM) Joint Venture with SAVSU® Technologies to Market Intelligent, Controlled Temperature Containers for Biologics investment picks
Single-Use Syringes and Bulk Dispensing Bags with Sterile Dockable Tubing Offer Improved Aseptic Processing of Clinical Cells and Tissues BOTHELL, Wash.
Sign-up for BioLife Solutions Launches Two New Product Packaging Options for BloodStor® and CryoStor® Freeze Media investment picks
2014/12/12
During an investor and analyst meeting hosted today in New York, BioLineRx Ltd.
Sign-up for BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform investment picks
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2014.
Sign-up for BioLineRx Reports Third Quarter 2014 Financial Results investment picks
BioLineRx Ltd.
Sign-up for BioLineRx to Report Third Quarter 2014 Results on November 10, 2014 investment picks
Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate,drisapersen, for Duchenne muscular dystrophy (DMD)   Drisapersen is currently under a rolling review as part of a New Drug Application process and has Orphan, Fast Track and Breakthrough Therapy designation by the FDA   Drisapersen, a potential first-to-market and best-in-class product for treating a large population of patients with a rare, fatal genetic disease represents up to 10,000 DMD patients   Follow-on products leveraging Prosensa's same technology platform in the pipeline target an additional 35,000 DMD patients in BioMarin's commercial territories   Investor conference call to be held today, November 24, 2014 at 5am PST (8am EST) SAN RAFAEL, Calif., Nov.
Sign-up for BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio investment picks
- VIMIZIM ® Sales Top $25 million in Second Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased SAN RAFAEL, Calif., Oct.
Sign-up for BioMarin Announces Third Quarter 2014 Financial Results investment picks
SAN RAFAEL, Calif., Sept.
Sign-up for BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines investment picks
- Jefferies Gene Therapy Summit on September 30 in Boston SAN RAFAEL, Calif., Sept.
Sign-up for BioMarin to Attend Upcoming Investor Conferences investment picks
Deutsche Bank BioFEST on December 2 SAN RAFAEL, Calif., Nov.
Sign-up for BioMarin to Attend Upcoming Investor Conferences investment picks
- J.P. Morgan Annual U.S. All Stars Conference in London on September 16 SAN RAFAEL, Calif., Sept.
Sign-up for BioMarin to Attend Upcoming Investor Conferences in London investment picks
SAN RAFAEL, Calif., Dec.
Sign-up for BioMarin to Host Analyst and Investor Day on December 10th in New York investment picks
SAN RAFAEL, Calif., Dec.
Sign-up for BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome investment picks
SAN RAFAEL, Calif., Dec.
Sign-up for BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: BIOLASE® to Host Third Quarter Financial Results Conference Call on November 4, 2014 to BioMed Realty Announces Repurchase At Option Of Holders And Redemption Of 3.75% Exchangeable Senior Notes Due 2030
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent